HAON Life Science

Thanks to Spark Crowdfunding for listing HAON Life Science in the Top 100 most ambitious Companies (pg 68/69) - in good company! https://lnkd.in/dvUsvbQr #Celltherapy #HAON #healthcareinnovation #neurodegenerativediseases #hopeforhie #neonatology #seriesa Mikey Creane Jatin Patel Moayed Hamza Mark O’Neill FCA

Alzheimer’s disease is devastating. But this MSC therapy (in Phase 2a trials) is showing some VERY promising results: So... why MSCs (mesenchymal stromal cells)? Unlike current AD treatments that primarily target amyloid or tau proteins, MSCs work through 4 unique (yet complementary) modes of action: - Provascular mechanisms - Anti-inflammation - Immunomodulation - Tissue repair Basically, it's a lot more comprehensive in tackling Alzheimers. The Trial Method Used: - A randomized, double-blind, placebo-controlled phase 2a trial across 10 centers in the U.S. - Four groups: placebo, low-dose (25M cells, single infusion), mid-dose (25M cells, four infusions), and high-dose (100M cells, four infusions). - Primary outcome: Safety evaluation (treatment-emergent serious adverse events). - Secondary/exploratory outcomes: Cognitive assessments, brain volume changes via MRI, and neuroinflammation markers. Results: - Great safety profile (No infusion-related reactions, hypersensitivities, or ARIAs) - Improved cognitive benefits - Whole brain atrophy slowed by ~48% (hippocampal atrophy by 61.9%) That last number is really important. Slower atrophy means neurons survive longer, potentially delaying cognitive decline. Meaning, memory centers are protected. The therapy is literally slowing Alzheimers at the structural level of the brain. Folks, this is really good news. Kudos to the team over at Longeveron Inc. And thank you to Michael Brown for highlighting this important work. Excited to see this therapy progress to the next stages of trials. What are your thoughts on this approach? Drop them in the comments.

It was wonderful to be in the audience at this week's IPHA Conference. The personal highlight for me was being there for the evening panel session featuring homegrown advanced therapy innovators in discussion with Matt Cooper. Nicki Panoskaltsis (TCD/St James's/NIBRT), Jane Farrar (TCD) and Mark O’Neill FCA (Haon Life Sciences) did a great job telling their very different stories working at the research, development and innovation coal-face. It was also tremendously gratifying that each of these world-leading innovators are either NIBRT research partners or members of Ireland's CGT Forum community. Each of them in their own unique way is representative of the green shoots emerging in Ireland's indigenous life science ecosystem, sitting alongside Ireland's long established excellence in biophama manufacturing. #CGTForum #advancedtherapeuticsireland #NIBRT

Great to discuss biotech innovation with Jane Farrar and Nicki Panoskaltsis @ipha conference last night and showcase the CanVas consortium plans: University College Cork INFANT Centre NIBRT National Institute for Bioprocessing Research and Training HiTech Health #iphaconference2025

🚨 𝐅𝐃𝐀 𝐀𝐩𝐩𝐫𝐨𝐯𝐞𝐬 𝐅𝐢𝐫𝐬𝐭 𝐌𝐒𝐂 𝐂𝐞𝐥𝐥 𝐓𝐡𝐞𝐫𝐚𝐩𝐲! Mesoblast achieves a historic milestone with FDA approval of Ryoncil®, the first-ever mesenchymal stromal cell (MSC) therapy in the U.S. Ryoncil is approved for steroid-refractory acute graft-versus-host disease (SR-aGvHD) in pediatric patients aged 2 months and older. 𝐊𝐞𝐲 𝐀𝐩𝐩𝐫𝐨𝐯𝐚𝐥 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬: 👉 TreatsSR-aGvHD, which has high mortality and limited treatment options. 👉 Efficacy: In pivotal trials, 70% of patients with severe disease responded within 28 days—a predictor of long-term survival. 👉 Milestone: First FDA-approved MSC therapy, showcasing the feasibility of cell-based treatments for inflammatory diseases and FDAs door opens. Interestingly, RYONCIL uses bone marrow-derived MSCs to suppress T-cell activation and modulate immune responses, reducing severe inflammation. Congratulations Mesoblast and team. Superb end to the year! #celltherapy #immunology #cellandgenetherapy #CGTweekly

🚀 Exciting News from the EIT Health Fast Track Programme! 🚀 Under our Fast Track initiative, 10 promising start-ups from our portfolio received exclusive mentoring support from our experts and bypassed the EIC Accelerator's initial application stage, advancing directly to the full application process. 🌟 🎉 Congratulations to our selected start-ups: Exhalation Technology Ltd NIB biotec Cellprothera HAON Life Science Corify EFM SensePilot Scicake CheckEye Innocens The EIC Accelerator supports innovative companies in developing and scaling up game-changing solutions, offering: 💶 Grant funding of up to 2,5 million € 💼 Equity investments of up to €10 million €, managed by the EIC Fund ✨ Are you ready to be part of the next success story? Learn more about our Fast Track Programme here: https://lnkd.in/eYyBJnkW

During #ScienceWeek, #HAON agree with the article below, Ireland and also Europe have a very significant opportunity to lead on regenerative cell therapy development.  #HAON's placental cell platform generates allogeneic (off-the -shelf) endothelial colony forming cells (ECFC) that pass the blood-brain barrier and home to sites of injury. We believe that regeneration has the potential to advance care for diseases with limited treatment options by changing the paradigm from small steps to transformational change. To learn more about our work at HAON, please check out a recent interview with the founders: https://lnkd.in/eBGZgjqx #ScienceWeek #ResearchIreland #HAON #EnterpriseIreland #Celltherapy #AdvancedTherapies

We also had the opportunity to sit down with Moayed Hamza and Mark O’Neill FCA from HAON Life Science, which develops investigational allogeneic candidates for neurologic, rare and other serious diseases. Their first focus indication is neonatal HIE – a type of newborn brain injury – that according to Nature has an incidence that varies between 1 and 3 per 1000 live births in developed countries and 2.3 to 30.6 per 1000 live births in developing countries. Yet, there are no current treatments available aside from cooling. Hamza and O'Neill tells BioStock that their platform is applicable in multiple neurodegenerative diseases, but that they aim for a first approval in neonatal HIE due to its high unmet medical need, lack of competition in the market and thus presents an opportunity for accelerated approval. Hear more about their progress in our interview!

We're entering new territory at CergenX! Our first product, the CergenX Wave device, is currently being tested on newborns in a hospital environment as part of a Feasibility Study. This non-interventional, observational study is designed to assess the usability of the device. The Feasibility Study is a key element of CergenX's DTIF partnership with the INFANT Research Centre at University College Cork. The study is part of the CergenX-led consortium, which was awarded €6.7m in non-dilutive grant funding last year from Enterprise Ireland and DTIF. Recruitment for the study is progressing well, with dozens of newborns already tested. This marks a significant milestone for CergenX, elevating the company to the next level. In a short period of time, the team has transformed a promising idea into a fully realised device that is now deployed in a busy hospital setting. Wave is poised to make a meaningful impact on newborns, their families, and healthcare professionals. The entire team at CergenX is proud of this achievement—the result of 18 months of hard work and perseverance. Our special thanks are extended to the team at INFANT Research Centre and Cork University Maternity Hospital (CUMH) for their instrumental role in launching and maintaining the study, as well as to the parents who consented to their newborns participating. Cork University Hospitals Group #MedTechInnovation #BrainInjury #AiForGood

It's #WorldCerebralPalsyDay 💚 ⁉ Did you know, an estimated 150 babies receive a Cerebral Palsy(CP) diagnosis in Ireland each year, and an estimated 3,000 children and young people and 9,500 adults are living with CP in Ireland? It is in fact the most common lifelong physical disability in Ireland. Earlier this year, we launched a new ground-breaking five-year research programme called ELEVATE - led by INFANT at University College Cork, partnered with Royal College of Surgeons in Ireland (RCSI) University of Medicine and Health Sciences and Trinity College Dublin, as well as the tertiary-level maternity hospitals. ELEVATE is co-funded by Research Ireland (formerly SFI) and the Cerebral Palsy Foundation (CPF), and aims to improve the prevention, detection and treatment of early brain injury and cerebral palsy in Ireland. By fostering collaboration between clinical, academic, and industry partners, as well as involving individuals with CP and their families from the outset, Ireland is set to become a global leader in CP research and care. Ultimately this programme aims to provide hope and better outcomes for children and families impacted by CP. Read more about #ELEVATE here: https://lnkd.in/egPrWiK4